Reprogramming of mesenchymal stem cells by oncogenes

Seminars in Cancer Biology

Volumn 32, Issue , 2015, Pages 18-31

  Eid, Josiane E ^a   Garcia, Christina B ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Mesenchymal; Oncogene; Reprogramming; Sarcoma; Stem

Indexed keywords

FUSED IN SARCOMA PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE H3; HYBRID PROTEIN; MICRORNA; POLYCOMB GROUP PROTEIN; REGULATOR PROTEIN; RNA BINDING PROTEIN EWS; SWI SNF BAF COMPLEX; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG;

CANCER STEM CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL LINEAGE; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; GENE; HISTONE METHYLATION; HUMAN; MESENCHYMAL STEM CELL; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOMATIC CELL; SS18 GENE; SSX GENE; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; SARCOMA;

CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STROMAL CELLS; ONCOGENES; SARCOMA; TRANSCRIPTION FACTORS;

EID: 84929956683     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.05.005     Document Type: Review

References (233)

1. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012, 136(2):133-138.
2. Yagi H., Soto-Gutierrez A., Parekkadan B., Kitagawa Y., Tompkins R.G., Kobayashi N., et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010, 19(6):667-679.
3. Domínguez-Bendala J., Lanzoni G., Inverardi L., Ricordi C. Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med 2012, 1:59-63.
4. DelaRosa O., Dalemans W., Lombardo E. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol 2012, 23(6):978-983.
5. Auletta J.J., Deans R.J., Bartholomew A.M. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119(8):1801-1809.
6. Watt S.M., Gullo F., van der Garde M., Markeson D., Camicia R., Khoo C.P., et al. The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br Med Bull 2013, 108:25-53.
7. Dwyer R.M., Khan S., Barry F.P., O'Brien T., Kerin M.J. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010, 1(3):25.
8. Barzilay R., Melamed E., Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells 2009, 27(10):2509-2515.
9. de Peppo G.M., Marcos-Campos I., Kahler D.J., Alsalman D., Shang L., Vunjak-Novakovic G., et al. Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci USA 2013, 110(21):8680-8685.
10. Deyle D.R., Khan I.F., Ren G., Wang P.R., Kho J., Schwarze U., et al. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther 2012, 20(1):204-213.
11. Cashman T.J., Gouon-Evans V., Costa K.D. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev 2013, 9(3):254-265.
12. Buccini S., Haider K.H., Ahmed R.P., Jiang S., Ashraf M. Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart. Basic Res Cardiol 2012, 107(6):301.
13. Xouri G., Christian S. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol 2010, 21(1):40-46.
14. Schepers K., Pietras E.M., Reynaud D., Flach J., Binnewies M., Garg T., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013, 13(3):285-299.
15. Koh B.I., Kang Y. The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells. EMBO Rep 2012, 13(5):412-422.
16. Jung Y., Kim J.K., Shiozawa Y., Wang J., Mishra A., Joseph J., et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013, 4:1795.
17. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563.
18. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29(1):11-19.
19. Galderisi U., Giordano A., Paggi M.G. The bad and the good of mesenchymal stem cells in cancer: boosters of tumor growth and vehicles for targeted delivery of anticancer agents. World J Stem Cells 2010, 2(1):5-12.
20. Helman L.J., Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3:685-694.
21. Rodriguez R., Rubio R., Menendez P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res 2012, 22(1):62-77.
22. Trucco M., Loeb D. Sarcoma stem cells: do we know what we are looking for?. Sarcoma 2012, 2012:291705.
23. Toguchida J., Nakayama T. Molecular genetics of sarcomas: applications to diagnoses and therapy. Cancer Sci 2009, 100(9):1573-1580.
24. Sparks R.L., Allen B.J., Zygmunt A.I., Strauss E.E. Loss of differentiation control in transformed 3T3T proadipocytes. Cancer Res 1993, 53(8):1770-1776.
25. Tzen C.Y., Filipak M., Scott R.E. Metaplastic change in mesenchymal stem cells induced by activated ras oncogene. Am J Pathol 1990, 137(5):1091-1102.
26. Klinken S.P., Alexander W.S., Adams J.M. Hemopoietic lineage switch: v-raf oncogene converts Emu-myc transgenic B cells into macrophages. Cell 1988, 53(6):857-867.
27. Del Valle L., Piña-Oviedo S., Perez-Liz G., Augelli B.J., Azizi S.A., Khalili K., et al. Bone marrow-derived mesenchymal stem cells undergo JCV T-antigen mediated transformation and generate tumors with neuroectodermal characteristics. Cancer Biol Ther 2010, 9(4).
28. Wang Z.Q., Grigoriadis A.E., Möhle-Steinlein U., Wagner E.F. A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J 1991, 10(9):2437-2450.
29. Jedlicka P. Ewing sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions. Int J Clin Exp Pathol 2010, 3(4):338-347.
30. Cavazzana A.O., Miser J.S., Jefferson J., Triche T.J. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 1987, 127(3):507-518.
31. Noguera R., Navarro S., Peydró-Olaya A., Llombart-Bosch A. Patterns of differentiation in extraosseous Ewing's sarcoma cells. An in vitro study. Cancer 1994, 73(3):616-624.
32. Torchia E.C., Jaishankar S., Baker S.J. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003, 63(13):34648.
33. Eliazer S., Spencer J., Ye D., Olson E., Ilaria R.L. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 2003, 23(2):482-492.
34. Rorie C.J., Thomas V.D., Chen P., Pierce H.H., O'Bryan J.P., Weissman B.E. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004, 64(4):1266-1277.
35. Hu-Lieskovan S., Zhang J., Wu L., Shimada H., Schofield D.E., Triche T.J. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005, 65(11):4633-4644.
36. Riggi N., Cironi L., Provero P., Suvà M.L., Kaloulis K., Garcia-Echeverria C., et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005, 65(24):11459-11468.
37. Castillero-Trejo Y., Eliazer S., Xiang L., Richardson J.A., Ilaria R.L. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res 2005, 65(19):8698-8705.
38. Tirode F., Laud-Duval K., Prieur A., Delorme B., Charbord P., Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007, 11(5):421-429.
39. Suvà M.L., Riggi N., Stehle J.C., Baumer K., Tercier S., Joseph J.M., et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009, 69(5):1776-1781.
40. Lessnick S.L., Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012, 7:145-159.
41. Staege M.S., Hutter C., Neumann I., Foja S., Hattenhorst U.E., Hansen G., et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004, 64(22):8213-8221.
42. van der Schaft D.W., Hillen F., Pauwels P., Kirschmann D.A., Castermans K., Egbrink M.G., et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 2005, 65(24):11520-11528.
43. Brown L.A., Rodaway A.R., Schilling T.F., Jowett T., Ingham P.W., Patient R.K., et al. Insights into early vasculogenesis revealed by expression of the ETS-domain transcription factor Fli-1 in wild-type and mutant zebrafish embryos. Mech Dev 2000, 90:237-252.
44. Gangwal K., Sankar S., Hollenhorst P.C., Kinsey M., Haroldsen S.C., Shah A.A., et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 2008, 105(29):10149-10154.
45. Erkizan H.V., Uversky V.N., Toretsky J.A. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 2010, 16(16):4077-4083.
46. Li X., McGee-Lawrence M.E., Decker M., Westendorf J.J. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem 2010, 111(4):933-943.
47. Riggi N., Suvà M.L., Suvà D., Cironi L., Provero P., Tercier S., et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008, 68(7):2176-8513.
48. Richter G.H., Plehm S., Fasan A., Rössler S., Unland R., Bennani-Baiti I.M., et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 2009, 106(13):5324-5329.
49. Riggi N., Suvà M.L., De Vito C., Provero P., Stehle J.C., Baumer K., et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010, 24(9):916-932.
50. De Vito C., Riggi N., Cornaz S., Suvà M.L., Baumer K., Provero P., et al. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 2012, 21(6):807-821.
51. De Vito C., Riggi N., Suvà M.L., Janiszewska M., Horlbeck J., Baumer K., et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS ONE 2011, 6(8):e23592.
52. Parrish J.K., Sechler M., Winn R.A., Jedlicka P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.541.
53. von Levetzow C., Jiang X., Gwye Y., von Levetzow G., Hung L., Cooper A., et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS ONE 2011, 6(4):e19305.
54. Douglas D., Hsu J.H., Hung L., Cooper A., Abdueva D., van Doorninck J., et al. BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 2008, 68:6507-6515.
55. Marshall A.D., Grosveld G.C. Alveolar rhabdomyosarcoma - the molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle 2012, 2(1):25.
56. Charytonowicz E., Cordon-Cardo C., Matushansky I., Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?. Cancer Lett 2009, 279(2):126-136.
57. Ren Y.X., Finckenstein F.G., Abdueva D.A., Shahbazian V., Chung B., Weinberg K.I., et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008, 68(16):6587-6597.
58. Charytonowicz E., Matushansky I., Doménech J.D., Castillo-Martín M., Ladanyi M., Cordon-Cardo C., et al. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin Transl Oncol 2012, 14(3):197-206.
59. Relaix F., Polimeni M., Rocancourt D., Ponzetto C., Schäfer B.W., Buckingham M. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 2003, 17(23):2950-2965.
60. Keller C., Arenkiel B.R., Coffin C.M., El-Bardeesy N., DePinho R.A., Capecchi M.R. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004, 18(21):2614-2626.
61. Kempf B.E., Vogt P.K. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. Cell Growth Differ 1999, 10(12):813-818.
62. Khan J., Bittner M.L., Saal L.H., Teichmann U., Azorsa D.O., Gooden G.C., et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA 1999, 96(23):13264-13269.
63. Cao L., Yu Y., Bilke S., Walker R.L., Mayeenuddin L.H., Azorsa D.O., et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010, 70(16):6497-6508.
64. Naini S., Etheridge K.T., Adam S.J., Qualman S.J., Bentley R.C., Counter C.M., et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008, 68(23):9583-9588.
65. Calhabeu F., Hayashi S., Morgan J.E., Relaix F., Zammit P.S. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene 2013, 32(5):651-662.
66. Walters Z.S., Villarejo-Balcells B., Olmos D., Buist T.W., Missiaglia E., Allen R., et al. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.46.
67. Ciarapica R., De Salvo M., Carcarino E., Bracaglia G., Adesso L., Leoncini P.P., et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.471.
68. Sánchez-García I., Rabbitts T.H. Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 1994, 91(17):7869-7873.
69. Zinszner H., Albalat R., Ron D. A novel effector domain from the RNA binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994, 8(21):2513-2526.
70. Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997, 151(3):735-744.
71. Adelmant G., Gilbert J.D., Freytag S.O. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J Biol Chem 1998, 273(25):15574-15581.
72. Pérez-Losada J., Pintado B., Gutiérrez-Adán A., Flores T., Bañares-González B., del Campo J.C., et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000, 19(20):2413-2422.
73. Pérez-Losada J., Sánchez-Martín M., Rodríguez-García M.A., Pérez-Mancera P.A., Pintado B., Flores T., et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 2000, 19(52):6015-6022.
74. Pérez-Mancera P.A., Vicente-Dueñas C., González-Herrero I., Sánchez-Martín M., Flores-Corral T., Sánchez-García I. Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. Carcinogenesis 2007, 28(10):2069-2073.
75. Riggi N., Cironi L., Provero P., Suvà M.L., Stehle J.C., Baumer K., et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006, 66(14):7016-7023.
76. Rubio R., García-Castro J., Gutiérrez-Aranda I., Paramio J., Santos M., Catalina P., et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 2010, 70(10):4185-4194.
77. Rodriguez R., Rubio R., Gutierrez-Aranda I., Melen G.J., Elosua C., García-Castro J., et al. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells 2011, 29(2):179-192.
78. Rodriguez R., Tornin J., Suarez C., Astudillo A., Rubio R., Yauk C., et al. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. Stem Cells 2013, 31(10):2061-2072.
79. Pérez-Mancera P.A., Bermejo-Rodríguez C., Sánchez-Martín M., Abollo-Jiménez F., Pintado B., Sánchez-García I. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS ONE 2008, 3(7):e2569.
80. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997, 94(1):237-241.
81. Charytonowicz E., Terry M., Coakley K., Telis L., Remotti F., Cordon-Cardo C., et al. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012, 122(3):886-898.
82. Powers C.A., Mathur M., Raaka B.M., Ron D., Samuels H.H. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 1998, 12(1):4-18.
83. Przybyl J., Jurkowska M., Rutkowski P., Debiec-Rychter M., Siedlecki J.A. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma 2012, 2012:249219.
84. Naka N., Takenaka S., Araki N., Miwa T., Hashimoto N., Yoshioka K., et al. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010, 28(7):1119-1131.
85. Haldar M., Hancock J.D., Coffin C.M., Lessnick S.L., Capecchi M.R. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007, 11(4):375-388.
86. Perani M., Ingram C.J., Cooper C.S., Garrett M.D., Goodwin G.H. Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene 2003, 22(50):8156-8167.
87. Lim F.L., Soulez M., Koczan D., Thiesen H.J., Knight J.C. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 1998, 17(15):2013-2018.
88. Eid J.E., Kung A.L., Scully R., Livingston D.M. p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. Cell 2000, 102:839-848.
89. Thaete C., Brett D., Monaghan P., Whitehouse S., Rennie G., Rayner E., et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet 1999, 8(4):585-591.
90. Ito T., Ouchida M., Ito S., Jitsumori Y., Morimoto Y., Ozaki T., et al. SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex. Lab Invest 2004, 84(11):1484-1490.
91. Perani M., Antonson P., Hamoudi R., Ingram C.J., Cooper C.S., Garrett M.D., et al. The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. J Biol Chem 2005, 280(52):42863-42876.
92. Soulez M., Saurin A.J., Freemont P.S., Knight J.C. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. Oncogene 1999, 18(17):2739-2746.
93. Barco R., Garcia C.B., Eid J.E. The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. PLoS ONE 2009, 4(4):e5060.
94. Garcia C.B., Shaffer C.M., Eid J.E. Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC Genomics 2012, 13:189.
95. Cironi L., Provero P., Riggi N., Janiszewska M., Suva D., Suva M.L., et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS ONE 2009, 4(11):e7904.
96. Garcia C.B., Shaffer C.M., Alfaro M.P., Smith A.L., Sun J., Zhao Z., et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma- associated oncogene SYT-SSX2. Oncogene 2012, 31(18):2323-2334.
97. Ishibe T., Nakayama T., Aoyama T., Nakamura T., Toguchida J. Neuronal differentiation of synovial sarcoma and its therapeutic application. Clin Orthop Relat Res 2008, 466(9):2147-2155.
98. Nagai M., Tanaka S., Tsuda M., Endo S., Kato H., Sonobe H., et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci USA 2001, 98(7):3843-3848.
99. Kadoch C., Crabtree G.R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013, 153(1):71-85.
100. Kohashi K., Oda Y., Yamamoto H., Tamiya S., Matono H., Iwamoto Y., et al. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol 2010, 23:981-990.
101. Lubieniecka J.M., de Bruijn D.R., Su L., van Dijk A.H., Subramanian S., van de Rijn M., et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008, 68(11):4303-4310.
102. Su L., Sampaio A.V., Jones K.B., Pacheco M., Goytain A., Lin S., et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 2012, 21(3):333-347.
103. de Bruijn D.R., van Dijk A.H., Willemse M.P., van Kessel A.G. The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. Oncogene 2008, 27(5):653-662.
104. de Bruijn D.R., dos Santos N.R., Thijssen J., Balemans M., Debernardi S., Linder B., et al. The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10. Oncogene 2001, 20(25):3281-3289.
105. Barham W., Frump A.L., Sherrill T.P., Garcia C.B., Saito-Diaz K., Vansaun M.N., et al. Targeting the wnt pathway in synovial sarcoma models. Cancer Discov 2013, 3(11):1286-1301.
106. Trautmann M., Sievers E., Aretz S., Kindler D., Michels S., Friedrichs N., et al. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.443.
107. Ishibe T., Nakayama T., Okamoto T., Aoyama T., Nishijo K., Shibata K.R., et al. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 2005, 11(7):2702-2712.
108. Tollervey J.R., Lunyak V.V. Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics 2012, 7(8):823-840.
109. Sindhu C., Samavarchi-Tehrani P., Meissner A. Transcription factor-mediated epigenetic reprogramming. J Biol Chem 2012, 287(37):30922-30931.
110. Woodbury D., Reynolds K., Black I.B. Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 2002, 96:908-917.
111. Prezioso C., Orlando V. Polycomb proteins in mammalian cell differentiation and plasticity. FEBS Lett 2011, 585(13):2067-2077.
112. Graf T., Enver T. Forcing cells to change lineages. Nature 2009, 462(7273):587-594.
113. Hong J.H., Yaffe M.B. TAZ: a β-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006, 5(2):176-179.
114. Shu J., Deng H. Lineage specifiers: new players in the induction of pluripotency. Genomics Proteomics Bioinform 2013, 10.1016/j.gpb.2013.09.005.
115. Apostolou E., Hochedlinger K. Chromatin dynamics during cellular reprogramming. Nature 2013, 502(7472):462-471.
116. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006, 20(9):1123-1136.
117. Hemming S., Cakouros D., Isenmann S., Cooper L., Menicanin D., Zannettino A., et al. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells 2013, [Epub ahead of print]. 10.1002/stem.1573.
118. Wei Y., Chen Y.H., Li L.Y., Lang J., Yeh S.P., Shi B., et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 2011, 13:87-94.
119. Caretti G., Di Padova M., Micales B., Lyons G.E., Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18(21):2627-2638.
120. Yu Y.L., Chou R.H., Shyu W.C., Hsieh S.C., Wu C.S., Chiang S.Y., et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med 2013, 5(4):531-547.
121. Bennani-Baiti I.M. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis. Epigenomics 2011, 3(6):715-732.
122. Strauss R., Hamerlik P., Lieber A., Bartek J. Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer. Mol Ther 2012, 20(5):887-897.
123. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423(6937):302-305.
124. Lessard J.A., Crabtree G.R. Chromatin regulatory mechanisms in pluripotency. Annu Rev Cell Dev Biol 2010, 26:503-532.
125. Jacobs J.J., Scheijen B., Voncken J.W., Kieboom K., Berns A., van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999, 13(20):2678-2690.
126. Asp P., Blum R., Vethantham V., Parisi F., Micsinai M., Cheng J., et al. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci USA 2011, 108:E149-E158.
127. Lee M.H., Jothi M., Gudkov A.V., Mal A.K. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res 2011, 71(11):3921-3931.
128. de la Serna I.L., Ohkawa Y., Imbalzano A.N. Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 2006, 7(6):461-473.
129. Staahl B.T., Tang J., Wu W., Sun A., Gitler A.D., Yoo A.S., et al. Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways. J Neurosci 2013, 33(25):10348-10361.
130. Albini S., Coutinho P., Malecova B., Giordani L., Savchenko A., Forcales S.V., et al. Epigenetic reprogramming of human embryonic stem cells into skeletal muscle cells and generation of contractile myospheres. Cell Rep 2013, 3(3):661-670.
131. Simone C., Forcales S.V., Hill D.A., Imbalzano A.N., Latella L., Puri P.L. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet 2004, 36(7):738-743.
132. Kadoch C., Hargreaves D.C., Hodges C., Elias L., Ho L., Ranish J., et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013, 45(6):592-601.
133. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007, 39(2):237-242.
134. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39:157-158.
135. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236.
136. Easwaran H., Johnstone S.E., Van Neste L., Ohm J., Mosbruger T., Wang Q., et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012, 22(5):837-849.
137. Gurtan A.M., Sharp P.A. The role of miRNAs in regulating gene expression networks. J Mol Biol 2013, 425(19):3582-3600.
138. Zaidi M.R., Okada Y., Chada K.K. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res 2006, 66(15):7453-7459.
139. Williams S.A., Maecker H.L., French D.M., Liu J., Gregg A., Silverstein L.B., et al. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 2011, 146(6):918-930.
140. Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J Pathol 2009, 217(4):469-482.
141. Sordella R., Jiang W., Chen G.C., Curto M., Settleman J. Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 2003, 113(2):147-158.
142. De Santa F., Totaro M.G., Prosperini E., Notarbartolo S., Testa G., Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007, 130(6):1083-1094.
143. Ficz G., Hore T.A., Santos F., Lee H.J., Dean W., Arand J., et al. FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell 2013, 13(3):351-359.
144. Ling L., Nurcombe V., Cool S.M. Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009, 433:1-7.
145. Merrill B.J. Develop-WNTs in somatic cell reprogramming. Cell Stem Cell 2008, 3(November (5)):465-466.
146. Sanges D., Cosma M.P. Reprogramming cell fate to pluripotency: the decision-making signalling pathways. Int J Dev Biol 2010, 54(11-12):1575-1587.
147. Lujan E., Wernig M. An indirect approach to generating specific human cell types. Nat Methods 2013, 10(1):44-45.
148. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
149. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
150. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.
151. Anokye-Danso F., Trivedi C.M., Juhr D., Gupta M., Cui Z., Tian Y., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8(4):376-388.
152. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26(11):1269-1275.
153. Zhu S., Li W., Zhou H., Wei W., Ambasudhan R., Lin T., et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010, 7(6):651-655.
154. Hou P., Li Y., Zhang X., Liu C., Guan J., Li H., et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341(6146):651-654.
155. Ichida J.K., Blanchard J., Lam K., Son E.Y., Chung J.E., Egli D., et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5(5):491-503.
156. Epsztejn-Litman S., Feldman N., Abu-Remaileh M., Shufaro Y., Gerson A., Ueda J., et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat Struct Mol Biol 2008, 15(11):1176-1183.
157. Gaspar-Maia A., Alajem A., Meshorer E., Ramalho-Santos M. Open chromatin in pluripotency and reprogramming. Nat Rev Mol Cell Biol 2011, 12(1):36-47.
158. Moon J.H., Heo J.S., Kim J.S., Jun E.K., Lee J.H., Kim A., et al. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Cell Res 2011, 21(9):1305-1315.
159. Malchenko S., Galat V., Seftor E.A., Vanin E.F., Costa F.F., Seftor R.E., et al. Cancer hallmarks in induced pluripotent cells: new insights. J Cell Physiol 2010, 225(2):390-393.
160. Melton C., Judson R.L., Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 2010, 463(7281):621-626.
161. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009, 137(4):647-658.
162. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751.
163. Peter M.E. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009, 8(6):843-852.
164. Suvà M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339(6127):1567-1570.
165. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
166. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
167. Battula V.L., Evans K.W., Hollier B.G., Shi Y., Marini F.C., Ayyanan A., et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 2010, 28(8):1435-1445.
168. Esteban M.A., Bao X., Zhuang Q., Zhou T., Qin B., Pei D. The mesenchymal-to-epithelial transition in somatic cell reprogramming. Curr Opin Genet Dev 2012, 22(5):423-428.
169. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273.
170. McDonald O.G., Wu H., Timp W., Doi A., Feinberg A.P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011, 18(8):867-874.
171. Tiwari N., Tiwari V.K., Waldmeier L., Balwierz P.J., Arnold P., Pachkov M., et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23(6):768-783.
172. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010, 12(10):982-992.
173. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009, 11(12):1487-1495.
174. Zhang Z., Filho M.S., Nör J.E. The biology of head and neck cancer stem cells. Oral Oncol 2012, 48(1):1-9.
175. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
176. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3(7):730-737.
177. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481(7381):306-313.
178. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
179. Vincent A., Van Seuningen I. On the epigenetic origin of cancer stem cells. Biochim Biophys Acta 2012, 1826(1):83-88.
180. Mimeault M., Batra S.K. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med 2013, S0098-2997(13)00059-9 [Epub ahead of print]. 10.1016/j.mam.2013.08.001.
181. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
182. Pérez-Caro M., Cobaleda C., González-Herrero I., Vicente-Dueñas C., Bermejo- Rodríguez C., Sánchez-Beato M., et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J 2009, 28(1):8-20.
183. Vicente-Dueñas C., Romero-Camarero I., González-Herrero I., Alonso-Escudero E., Abollo-Jiménez F., Jiang X., et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J 2012, 31(18):3704-3717.
184. Vicente-Dueñas C., Fontán L., Gonzalez-Herrero I., Romero-Camarero I., Segura V., Aznar M.A., et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci USA 2012, 109(26):10534-10539.
185. Romero-Camarero I., Jiang X., Natkunam Y., Lu X., Vicente-Dueñas C., Gonzalez- Herrero I., et al. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nat Commun 2013, 4:1338. 10.1038/ncomms2334.
186. Vicente-Dueñas C., Romero-Camarero I., Cobaleda C., Sánchez-García I. Function of oncogenes in cancer development: a changing paradigm. EMBO J 2013, 32(11):1502-1513.
187. Ladewig J., Koch P., Brüstle O. Leveling Waddington: the emergence of direct programming and the loss of cell fate hierarchies. Nat Rev Mol Cell Biol 2013, 14(4):225-236.
188. Guo Y., Costa R., Ramsey H., Starnes T., Vance G., Robertson K., et al. The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci USA 2002, 99(6):3663-3667.
189. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999, 35(14):1941-1953.
190. Prindull G., Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 2004, 103(8):2892-2899.
191. Muñoz P., Iliou M.S., Esteller M. Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol 2012, 6(6):620-636.
192. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
193. Alcantara Llaguno S., Chen J., Kwon C.H., Jackson E.L., Li Y., Burns D.K., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
194. Cozzio A., Passegué E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003, 17(24):3029-3035.
195. Liu Y., Clem B., Zuba-Surma E.K., El-Naggar S., Telang S., Jenson A.B., et al. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell 2009, 4(4):336-347.
196. Seigel G.M., Campbell L.M., Narayan M., Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis 2005, 11:729-737.
197. Suvà M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014, S0092-8674(14)00229-3 [Epub ahead of print]. 10.1016/j.cell.2014.02.030.
198. Ischenko I., Zhi J., Moll U.M., Nemajerova A., Petrenko O. Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci USA 2013, 110(10):3937-3942.
199. Scaffidi P., Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011, 13(9):1051-1061.
200. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2(4):333-344.
201. Schwitalla S., Fingerle A.A., Cammareri P., Nebelsiek T., Göktuna S.I., Ziegler P.K., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152(1-2):25-38.
202. Zabierowski S.E., Baubet V., Himes B., Li L., Fukunaga-Kalabis M., Patel S., et al. Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells 2011, 29(11):1752-1762.
203. Liu K1, Jiang M., Lu Y., Chen H., Sun J., Wu S., et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 2013, 12(3):304-315.
204. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463(7279):318-325.
205. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17(4):362-375.
206. Friedmann-Morvinski D., Bushong E.A., Ke E., Soda Y., Marumoto T., Singer O., et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012, 338(6110):1080-1084.
207. Basu-Roy U., Basilico C., Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett 2013, 338(1):158-167.
208. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008, 105(33):11851-11856.
209. Bazzoli E., Pulvirenti T., Oberstadt M.C., Perna F., Wee B., Schultz N., et al. MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell 2012, 11(6):836-844.
210. Hatley M.E., Tang W., Garcia M.R., Finkelstein D., Millay D.P., Liu N., et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 2012, 22(4):536-546.
211. Youssef K.K., Lapouge G., Bouvree K., Rorive S., Brohee S., Appelstein O., et al. Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor like fate during basal cell carcinoma initiation. Nat Cell Biol 2012, 14:1282-1294.
212. Eminli S., Foudi A., Stadtfeld M., Maherali N., Ahfeldt T., Mostoslavsky G., et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009, 41(9):968-976.
213. Lin C., Yu C., Ding S. Toward directed reprogramming through exogenous factors. Curr Opin Genet Dev 2013, 23(5):519-525.
214. Zhu S., Rezvani M., Harbell J., Mattis A.N., Wolfe A.R., Benet L.Z., et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014, 508(7494):93-97. [Epub 2014 Feb 23]. 10.1038/nature13020.
215. Ohnishi K., Semi K., Yamamoto T., Shimizu M., Tanaka A., Mitsunaga K., et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014, 156(4):663-677.
216. Wille J.J., Scott R.E. Suppression of tumorigenicity by the cell-cycle-dependent control of cellular differentiation and proliferation. Int J Cancer 1986, 37(6):875-881.
217. Estervig D.N., Maercklein P.B., Scott R.E. Resistance to neoplastic transformation induced by nonterminal differentiation. Cancer Res 1989, 49(4):1008-1013.
218. Tzen C.Y., Maercklein P.B., Scott R.E. Differentiation can convey resistance to transformation by activated ras oncogene. Anticancer Res 1990, 10(5A):1329-1334.
219. Kulesa P.M., Kasemeier-Kulesa J.C., Teddy J.M., Margaryan N.V., Seftor E.A., Seftor R.E., et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci USA 2006, 103(10):3752-3757.
220. Joel M., Sandberg C.J., Boulland J.L., Vik-Mo E.O., Langmoen I.A., Glover J.C. Inhibition of tumor formation and redirected differentiation of glioblastoma cells in a xenotypic embryonic environment. Dev Dyn 2013, 242(9):1078-1093.
221. Zhang X., Cruz F.D., Terry M., Remotti F., Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013, 32(18):2249-2260.
222. Lotem J., Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol 2002, 12(5):339-346.
223. Rapino F., Robles E.F., Richter-Larrea J.A., Kallin E.M., Martinez-Climent J.A., Graf T. C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity. Cell Rep 2013, 3(4):1153-1163.
224. Papetti M., Skoultchi A.I. Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1. Mol Cancer Res 2007, 5(10):1053-1062.
225. Matushansky I., Radparvar F., Skoultchi A.I. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc Natl Acad Sci USA 2000, 97(26):14317-14322.
226. Schenk T., Chen W.C., Göllner S., Howell L., Jin L., Hebestreit K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18(4):605-611.
227. Yeh J.R.J., Munson K.M. Zebrafish small molecule screen in reprogramming/cell fate modulation. Methods Mol Biol 2010, 636:317-327.
228. Siddiqi S., Mills J., Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther 2010, 5(1):63-73.
229. Ito T., Ouchida M., Morimoto Y., Yoshida A., Jitsumori Y., Ozaki T., et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005, 224(2):311-319.
230. Uren A., Toretsky J.A. Pediatric malignancies provide unique cancer therapy targets. Curr Opin Pediatr 2005, 17(1):14-19.
231. Li W., Li K., Wei W., Ding S. Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 2013, 13(3):270-283.
232. Firestone A.J., Chen J.K. Controlling destiny through chemistry: small-molecule regulators of cell fate. ACS Chem Biol 2010, 5(1):15-34.
233. Federation A.J., Bradner J.E., Meissner A. The use of small molecules in somatic-cell reprogramming. Trends Cell Biol 2013, S0962-8924(13)00168-2 [Epub ahead of print]. 10.1016/j.tcb.2013.09.011.